CN114466849B - 作为isoqc和/或qc酶的抑制剂的n-取代的-3,4-(稠合5-环)-5-苯基-吡咯烷-2-酮化合物 - Google Patents
作为isoqc和/或qc酶的抑制剂的n-取代的-3,4-(稠合5-环)-5-苯基-吡咯烷-2-酮化合物 Download PDFInfo
- Publication number
- CN114466849B CN114466849B CN202080056962.2A CN202080056962A CN114466849B CN 114466849 B CN114466849 B CN 114466849B CN 202080056962 A CN202080056962 A CN 202080056962A CN 114466849 B CN114466849 B CN 114466849B
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- compound according
- independently
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185997.4 | 2019-07-12 | ||
| EP19185997 | 2019-07-12 | ||
| PCT/EP2020/069630 WO2021009068A1 (en) | 2019-07-12 | 2020-07-10 | N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114466849A CN114466849A (zh) | 2022-05-10 |
| CN114466849B true CN114466849B (zh) | 2024-07-12 |
Family
ID=67262155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080056962.2A Expired - Fee Related CN114466849B (zh) | 2019-07-12 | 2020-07-10 | 作为isoqc和/或qc酶的抑制剂的n-取代的-3,4-(稠合5-环)-5-苯基-吡咯烷-2-酮化合物 |
Country Status (12)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717089A3 (en) | 2021-08-02 | 2026-06-24 | Syngenta Crop Protection AG | Microbiocidal pyrazole derivatives |
| AU2022203580A1 (en) * | 2021-09-17 | 2023-04-06 | Academia Sinica | Methods of Increasing Cell Phagocytosis |
| EP4447682A1 (en) | 2021-12-17 | 2024-10-23 | Syngenta Crop Protection AG | Microbiocidal pyrazole derivatives |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| PY2403614A (es) | 2023-01-27 | 2025-09-11 | Syngenta Crop Protection Ag | Derivados de pirazol microbiocidas |
| PY2404467A (es) | 2023-02-01 | 2025-03-31 | Syngenta Crop Protection Ag | Composiciones fungicidas |
| EP4455142A1 (en) | 2023-04-26 | 2024-10-30 | Scenic Immunology B.V. | Novel inhibitor of qpctl and/or qc |
| PY2447478A (es) | 2023-06-14 | 2025-03-18 | Syngenta Crop Protection Ag | Composiciones fungicidas |
| WO2025114167A1 (en) | 2023-11-28 | 2025-06-05 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| AR134999A1 (es) | 2024-02-02 | 2026-05-20 | Syngenta Crop Protection Ag | Derivados de pirazol microbiocidas |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025224308A1 (en) * | 2024-04-25 | 2025-10-30 | Scenic Immunology B.V. | Qpctl inhibitors |
| WO2026022173A1 (en) | 2024-07-26 | 2026-01-29 | Syngenta Crop Protection Ag | Microbiocidal pyrazole compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105408335A (zh) * | 2013-05-27 | 2016-03-16 | 诺华股份有限公司 | 吡唑并吡咯烷衍生物及其在治疗疾病中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011002106A (es) * | 2008-09-04 | 2011-04-07 | Probiodrug Ag | Inhibidores novedosos. |
| AU2014272695B2 (en) * | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| WO2019022600A1 (en) * | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47 |
-
2020
- 2020-07-10 CA CA3147154A patent/CA3147154A1/en active Pending
- 2020-07-10 BR BR112022000505A patent/BR112022000505A8/pt unknown
- 2020-07-10 US US17/626,614 patent/US20230077723A1/en not_active Abandoned
- 2020-07-10 KR KR1020227004600A patent/KR20220054293A/ko not_active Ceased
- 2020-07-10 CN CN202080056962.2A patent/CN114466849B/zh not_active Expired - Fee Related
- 2020-07-10 PH PH1/2022/550079A patent/PH12022550079A1/en unknown
- 2020-07-10 MX MX2022000521A patent/MX2022000521A/es unknown
- 2020-07-10 JP JP2022501167A patent/JP2022542540A/ja active Pending
- 2020-07-10 EP EP20743091.9A patent/EP3997091A1/en not_active Withdrawn
- 2020-07-10 AU AU2020312647A patent/AU2020312647A1/en not_active Abandoned
- 2020-07-10 WO PCT/EP2020/069630 patent/WO2021009068A1/en not_active Ceased
-
2022
- 2022-01-12 IL IL289784A patent/IL289784A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105408335A (zh) * | 2013-05-27 | 2016-03-16 | 诺华股份有限公司 | 吡唑并吡咯烷衍生物及其在治疗疾病中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3997091A1 (en) | 2022-05-18 |
| MX2022000521A (es) | 2022-06-14 |
| PH12022550079A1 (en) | 2023-04-12 |
| BR112022000505A2 (pt) | 2022-03-22 |
| BR112022000505A8 (pt) | 2022-04-12 |
| CN114466849A (zh) | 2022-05-10 |
| AU2020312647A1 (en) | 2022-02-24 |
| KR20220054293A (ko) | 2022-05-02 |
| WO2021009068A1 (en) | 2021-01-21 |
| US20230077723A1 (en) | 2023-03-16 |
| IL289784A (en) | 2022-03-01 |
| JP2022542540A (ja) | 2022-10-05 |
| CA3147154A1 (en) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114466849A (zh) | 作为isoqc和/或qc酶的抑制剂的n-取代的-3,4-(稠合5-环)-5-苯基-吡咯烷-2-酮化合物 | |
| TWI874645B (zh) | 作為il-17調節劑之咪唑并嗒類 | |
| CN106061976B (zh) | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 | |
| KR101837223B1 (ko) | 피리디논/피라지논, 그의 제조 방법 및 사용 방법 | |
| CN112105385A (zh) | Irak降解剂和其用途 | |
| CN112533913A (zh) | 新颖化合物 | |
| TWI773651B (zh) | 醫藥化合物 | |
| TWI845638B (zh) | Eed及prc2調節劑之巨環唑并吡啶衍生物 | |
| TW201722933A (zh) | 苯內醯胺化合物 | |
| US20240400518A1 (en) | Sos1 inhibitor and use thereof | |
| CN108026105A (zh) | TGFβ受体拮抗剂 | |
| JP7808733B2 (ja) | 置換オキソイソインドリニルピペリジン-2,6-ジオン化合物 | |
| CN112513021A (zh) | RORγ拮抗剂及其在药物中的应用 | |
| CN109476638B (zh) | 吡唑衍生物、其组合物及治疗用途 | |
| WO2023143401A1 (zh) | 作为masp-2抑制剂的化合物、药物组合物及其制备方法和用途 | |
| HK40126737A (en) | Antiviral pyrazolopyridinone compounds | |
| HK40110226A (en) | Fused ring compounds | |
| HK40109856A (en) | Fused ring compounds | |
| HK40110213A (en) | Fused ring compounds | |
| HK40110795A (en) | Fused ring compounds | |
| HK40112670A (en) | 5-[7-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-1,2,3,4 tetrahydroisoquinolin-6-y l]-1h-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| HK40059756B (en) | Compounds useful as kinase inhibitors | |
| HK40059212B (en) | Compounds useful as kinase inhibitors | |
| HK40109663A (en) | Lactams as cbl-b inhibitors selective over c-cbl | |
| HK40069881B (en) | Antiviral pyrazolopyridinone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20240712 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |